Prostate cancer survivorship research focuses largely on oncological outcome; however, fewer studies are available that assess the effects of prostate cancer and its treatment on bladder function.

A study of NHANES 2005-2020 data found that the prevalence of overactive bladder among men in the US increased significantly from 11.7% in 2009-2014 to 14.5% in 2015-2020. Overactive bladder (OAB) ...

Chinese investigators evaluated 15 years' worth of data from more than 18,000 adult men in the U.S. to better characterize OAB and its risk factors. The overall presence of OAB increased significantly ...

Men with overactive bladder had significant 95% reduced odds of urinary tract cancers compared with a reference group of men with urolithiasis, after adjusting for age. Overactive bladder (OAB) is ...

Please provide your email address to receive an email when new articles are posted on . The proportion of men with overactive bladder increased significantly from 2015 to 2020. Results showed ...

"My bladder is ruining my life," Mr. X said as he sat down on the exam table, already nervous about his first time seeing a urologist. He had considered skipping his appointment, but he simply can't ...

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for ...

Overactive bladder is most common in adults over 65 but can also be due to hormonal changes. Maintaining a healthy weight, eating right, and staying hydrated can help control surprise leaks. If ...

Credit: Shutterstock. Vibegron is an oral, small molecule beta-3 adrenergic receptor agonist. A phase 3 study evaluating the efficacy and safety of vibegron in men with overactive bladder (OAB) ...

Dear Dr. Roach: I’m an 81-year-old man. About two years ago, I began to realize that my testicles were shrinking, and they are now about the size of a marble. I have asked my primary care doctor and ...

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for urologic ...